Rybelsus 7 Mg 10 Tablets

Rybelsus 7 Mg 10 Tablets

Description:

Rybelsus 7 mg is an oral prescription diabetes medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, used to improve blood sugar control in adults with type 2 diabetes mellitus. It is part of modern diabetes care and offers a tablet alternative to injectable GLP-1 therapies. Rybelsus 7 mg helps lower blood glucose levels, supports HbA1c reduction, and may assist with weight management as part of a comprehensive treatment plan including diet and exercise. This product is a medicine and should be used only under medical supervision.

Indications:

• Management of type 2 diabetes mellitus in adults to improve glycemic control.
• Used as monotherapy when metformin is not tolerated or contraindicated, or in combination with other antidiabetic medications (such as metformin, SGLT2 inhibitors, or insulin) as prescribed by a physician.
• Helps reduce elevated fasting and postprandial blood glucose levels.
• May support weight reduction and appetite control in adults with type 2 diabetes as part of an overall diabetes management plan (diet, exercise, lifestyle changes).
• Helps reduce the risk of long-term diabetes complications associated with poor glycemic control when used consistently as prescribed.

Active Ingredients / Key Components:

• Semaglutide – 7 mg per tablet (GLP-1 receptor agonist).
• Excipients (tablet core and coating) – exact composition and concentrations are not specified in the available product information; please refer to the official package leaflet for full excipient list.

Dosage & Administration / How to Use:

• Rybelsus is for oral use only and must be taken exactly as prescribed by your doctor.
• Usual dosing schedule (for adults with type 2 diabetes):
  - Treatment is typically initiated with 3 mg once daily for 30 days (starter dose – not for glycemic control, but to improve gastrointestinal tolerability).
  - After at least 30 days on 3 mg, the dose is increased to 7 mg once daily.
  - Your doctor may further increase the dose to 14 mg once daily if additional glycemic control is needed.
  Note: Only the 7 mg strength is included in this pack; dose adjustments and combinations with other strengths must be guided by your physician.
• Take Rybelsus once daily on an empty stomach, with no more than 120 ml of plain water.
• Swallow the tablet whole; do not split, crush, or chew.
• Wait at least 30 minutes after taking Rybelsus before eating, drinking (anything other than up to 120 ml water), or taking any other oral medicines.
• Try to take it at the same time every day to maintain consistent blood levels.
• If you miss a dose and it is more than 12 hours until your next scheduled dose, take the missed dose as soon as you remember. If it is less than 12 hours to the next dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose.
• Use in special populations (elderly, renal or hepatic impairment) must be individualized by the prescribing physician.
• Do not stop or change your dose without consulting your doctor, as this may affect your blood sugar control.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by enhancing glucose-dependent insulin secretion and reducing inappropriate glucagon release.
• Helps lower HbA1c levels, contributing to better long-term blood sugar management and reduced risk of diabetes-related complications.
• Slows gastric emptying, which can help reduce postprandial (after-meal) blood glucose spikes.
• Acts on GLP-1 receptors in appetite-regulation centers in the brain, which may help decrease appetite and support weight reduction when combined with diet and exercise.
• Provides a convenient oral GLP-1 option for patients who prefer tablets over injectable GLP-1 therapies, potentially improving treatment adherence.
• Can be used in combination with other antidiabetic agents as part of a comprehensive, individualized diabetes management plan.

Warnings & Contraindications:

• Use only under the supervision of a healthcare professional experienced in the management of diabetes.
• Contraindicated in patients with known hypersensitivity to semaglutide or any of the excipients.
• Not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Not a substitute for insulin in insulin-dependent patients.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs.
• May increase the risk of gastrointestinal adverse reactions (nausea, vomiting, diarrhea); dose escalation should follow medical guidance to improve tolerability.
• Use with caution in patients with severe renal impairment or hepatic impairment; dose and monitoring should be individualized by the physician.
• Patients with diabetic retinopathy should be monitored closely, as GLP-1 receptor agonists may be associated with worsening of retinopathy in some individuals.
• Risk of hypoglycemia is increased when used in combination with insulin or sulfonylureas; dose adjustment of concomitant therapy may be required.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. The safety of semaglutide in pregnancy and lactation is not well established; your doctor will decide whether to discontinue the medicine or avoid pregnancy during treatment.
• Consult your doctor before use if you have a history of thyroid disease, pancreatitis, severe gastrointestinal disease, or other significant medical conditions.
• Do not use beyond the expiry date printed on the pack.
• Keep out of reach of children.
• This product is a prescription medicine and must not be used without a valid medical prescription and regular medical follow-up.

Side Effects:

• Common side effects: nausea, vomiting, diarrhea, abdominal pain, decreased appetite, indigestion, constipation, and bloating. These are usually mild to moderate and may decrease over time as your body adjusts to the medicine.
• Other possible side effects: headache, fatigue, dizziness, belching, gastroesophageal reflux, and slight weight loss.
• Hypoglycemia (low blood sugar) may occur, especially when used with insulin or sulfonylureas. Symptoms include sweating, shakiness, hunger, confusion, palpitations, and headache. Monitor blood glucose regularly and follow your doctor’s advice on dose adjustments.
• Serious but less common side effects: pancreatitis (severe, persistent abdominal pain that may radiate to the back, with or without vomiting), allergic reactions (rash, itching, swelling, difficulty breathing), worsening diabetic retinopathy, and severe gastrointestinal problems. Seek immediate medical attention if any of these occur.
• If you experience any unusual or persistent symptoms, contact your healthcare provider promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not store above the temperature specified on the outer packaging (refer to the official leaflet for exact storage temperature if needed). Protect from moisture and do not use if the blister is damaged.

Specifications:

• Product type: Prescription antidiabetic medicine (GLP-1 receptor agonist).
• Strength: 7 mg semaglutide per tablet.
• Form: Oral tablet.
• Pack size: 10 tablets per pack.
• Intended use: Adults with type 2 diabetes mellitus, as prescribed by a physician.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.